Sort   by:  
 Page size 
UnknownSouthwest Oncology Group S0008: a phase III trial of high-dose interferon Alfa-2b versus cisplatin, vinblastine, and dacarbazine, plus interleukin-2 and interferon in patients with high-risk melanoma--an intergroup study of cancer and leukemia Group B, Children's Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group.
Not available
S-EPMC4226807 | biostudies-literature
UnknownTotal body irradiation, etoposide, cyclophosphamide, and autologous peripheral blood stem-cell transplantation followed by randomization to therapy with interleukin-2 versus observation for patients with non-Hodgkin lymphoma: results of a phase 3 randomized trial by the Southwest Oncology Group (SWOG 9438).
Not available
S-EPMC2288718 | biostudies-literature
UnknownFeline leukaemia virus (FeLV) infection in domestic pet cats in Australia and New Zealand: Guidelines for diagnosis, prevention and management.
Not available
S-EPMC12500364 | biostudies-literature
UnknownConsiderations to Support Use of Patient-Reported Outcomes Measurement Information System Pediatric Measures in Ambulatory Clinics.
Not available
S-EPMC7914197 | biostudies-literature
UnknownNutrient scavenging-fueled growth in pancreatic cancer depends on caveolae-mediated endocytosis under nutrient-deprived conditions.
Not available
S-EPMC10906919 | biostudies-literature
UnknownA phase II study (AARDVARC) of AZD4635 in combination with durvalumab and cabazitaxel in patients with progressive, metastatic, castration-resistant prostate cancer.
Not available
S-EPMC11190476 | biostudies-literature
UnknownCytogenetic prognostication within medulloblastoma subgroups.
Not available
S-EPMC3948094 | biostudies-literature
UnknownTime-resolved cryo-EM particle stacks
Not available
EMPIAR-13621 | biostudies-other
UnknownGlutamine-stabilized filament form of Glutamine Synthetase under turnover conditions
Not available
EMPIAR-13622 | biostudies-other
UnknownPatient-reported outcomes for patients with metastatic castration-resistant prostate cancer receiving docetaxel and Atrasentan versus docetaxel and placebo in a randomized phase III clinical trial (SWOG S0421).
Not available
S-EPMC5997724 | biostudies-literature
Sort   by:  
 Page size